Prader-Willi Syndrome Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | 9 Meters Biopharma, Aardvark Therapeutics, Jazz Pharma

The Prader-Willi Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Prader-Willi Syndrome Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prader-Willi Syndrome Market.

Some of the key takeaways from the Prader-Willi Syndrome Pipeline Report:

• Companies across the globe are diligently working toward developing novel Prader-Willi Syndrome treatment therapies with a considerable amount of success over the years. 
• Prader-Willi Syndrome companies working in the treatment market are Meters Biopharma, Beryl Therapeutics, Helsinn, ConSynance Therapeutics, Neuren Pharmaceuticals, Compound Jazz Pharmaceuticals, Aardvark Therapeutics, Harmony Biosciences, Biospherics.net, Soleno Therapeutics, and others, are developing therapies for the Prader-Willi Syndrome treatment 

• Emerging Prader-Willi Syndrome therapies in the different phases of clinical trials are- NM-136 9, HU-671, HM 04, CSTI 500, NNZ-2591, CBDV, ARD-101, Pitolisant, BSN-175, DCCR, and others are expected to have a significant impact on the Prader-Willi Syndrome market in the coming years.   
• In January 2023, “Soleno Therapeutics began a trial named ‘An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome.’ The objective of this study is to assess the extended safety profile of DCCR (diazoxide choline) extended-release tablets in individuals diagnosed with Prader-Willi syndrome.”
• In July 2022, “Soleno Therapeutics, Inc. shared an update on their discussions with the U.S. Food and Drug Administration (FDA) concerning the advancement of the once-daily DCCR (diazoxide choline) extended-release tablets for treating Prader-Willi syndrome (PWS). As per recent discussions, the FDA recognized that data from a suggested randomized withdrawal phase of Study C602 could potentially resolve their concerns regarding the comprehensive efficacy data required for submitting a New Drug Application (NDA) for DCCR.”

Prader-Willi Syndrome Overview

Prader-Willi syndrome (PWS) is a genetic condition affecting multiple systems, commonly identified in infancy through symptoms like lethargy, reduced muscle tone (hypotonia), feeding challenges, inadequate weight gain, and growth issues due to hormone deficiencies. This syndrome occurs equally in males and females across all ethnic groups and is acknowledged as the leading genetic cause of severe childhood obesity.

Get a Free Sample PDF Report to know more about Prader-Willi Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/prader-willi-syndrome-pipeline-insight

Emerging Prader-Willi Syndrome Drugs Under Different Phases of Clinical Development Include:

• NM-136 9: Meters Biopharma
• HU-671: Beryl Therapeutics
• HM 04: Helsinn
• CSTI 500: ConSynance Therapeutics
• NNZ-2591: Neuren Pharmaceuticals
• CBDV: Compound Jazz Pharmaceuticals
• ARD-101: Aardvark Therapeutics
• Pitolisant: Harmony Biosciences
• BSN-175: Biospherics.net
• DCCR: Soleno Therapeutics

Prader-Willi Syndrome Route of Administration

Prader-Willi Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Prader-Willi Syndrome Molecule Type

Prader-Willi Syndrome Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Prader-Willi Syndrome Pipeline Therapeutics Assessment

• Prader-Willi Syndrome Assessment by Product Type
• Prader-Willi Syndrome By Stage and Product Type
• Prader-Willi Syndrome Assessment by Route of Administration
• Prader-Willi Syndrome By Stage and Route of Administration
• Prader-Willi Syndrome Assessment by Molecule Type
• Prader-Willi Syndrome by Stage and Molecule Type

DelveInsight’s Prader-Willi Syndrome Report covers around 18+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Prader-Willi Syndrome product details are provided in the report. Download the Prader-Willi Syndrome pipeline report to learn more about the emerging Prader-Willi Syndrome therapies

Some of the key companies in the Prader-Willi Syndrome Therapeutics Market include:

Key companies developing therapies for Prader-Willi Syndrome are – 9 Meters Biopharma Inc, Aardvark Therapeutics Inc, Altamira Therapeutics Ltd, Benuvia Therapeutics Inc, Beryl Therapeutics Inc, Biomind Labs Inc, Bioprojet SCR, Carmot Therapeutics Inc, ConSynance Therapeutics Inc, and Ferring International Center SA, and others.

Prader-Willi Syndrome Pipeline Analysis:

The Prader-Willi Syndrome pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Prader-Willi Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prader-Willi Syndrome Treatment.
• Prader-Willi Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prader-Willi Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prader-Willi Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Prader-Willi Syndrome drugs and therapies

Prader-Willi Syndrome Pipeline Market Drivers

• Rising incidence of Prader-Willi Syndrome, increased Focus on Disease Management and early Diagnosis are some of the important factors that are fueling the Prader-Willi Syndrome Market.

Prader-Willi Syndrome Pipeline Market Barriers

• However, presence of complications associated with the diseases, lack of awareness and other factors are creating obstacles in the Prader-Willi Syndrome Market growth.

Scope of Prader-Willi Syndrome Pipeline Drug Insight    

• Coverage: Global
• Key Prader-Willi Syndrome Companies: Meters Biopharma, Beryl Therapeutics, Helsinn, ConSynance Therapeutics, Neuren Pharmaceuticals, Compound Jazz Pharmaceuticals, Aardvark Therapeutics, Harmony Biosciences, Biospherics.net, Soleno Therapeutics, and others
• Key Prader-Willi Syndrome Therapies: NM-136 9, HU-671, HM 04, CSTI 500, NNZ-2591, CBDV, ARD-101, Pitolisant, BSN-175, DCCR, and others
• Prader-Willi Syndrome Therapeutic Assessment: Prader-Willi Syndrome current marketed and Prader-Willi Syndrome emerging therapies
• Prader-Willi Syndrome Market Dynamics: Prader-Willi Syndrome market drivers and Prader-Willi Syndrome market barriers 

Request for Sample PDF Report for Prader-Willi Syndrome Pipeline Assessment and clinical trials

Table of Contents

1. Prader-Willi Syndrome Report Introduction

2. Prader-Willi Syndrome Executive Summary

3. Prader-Willi Syndrome Overview

4. Prader-Willi Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Prader-Willi Syndrome Pipeline Therapeutics

6. Prader-Willi Syndrome Late Stage Products (Phase II/III)

7. Prader-Willi Syndrome Mid Stage Products (Phase II)

8. Prader-Willi Syndrome Early Stage Products (Phase I)

9. Prader-Willi Syndrome Preclinical Stage Products

10. Prader-Willi Syndrome Therapeutics Assessment

11. Prader-Willi Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Prader-Willi Syndrome Key Companies

14. Prader-Willi Syndrome Key Products

15. Prader-Willi Syndrome Unmet Needs

16 . Prader-Willi Syndrome Market Drivers and Barriers

17. Prader-Willi Syndrome Future Perspectives and Conclusion

18. Prader-Willi Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services